Montelukast Accord Healthcare (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Accord Healthcare, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in patients requiring anti‑inflammatory therapy.

GNH USA supplies Montelukast Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to control respiratory and allergic conditions. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Blood dyscrasias: neutropenia or eosinophilia. - Severe skin reactions: Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline control before adding Montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Montelukast plasma levels. - Phenobarbital or rifampin: may markedly reduce Montelukast exposure.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants: may heighten risk of neuropsychiatric effects. - Beta‑agonists: additive bronchodilator effect may require dose adjustment. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.